---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-014642"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2025-04-21T23:59:59+00:00"
generated_at: "2026-05-23T10:15:49.364281+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunovant CEO Pete Salzmann retires; Eric Venker appointed; IMVT-1402 adds SjD and CLE indications

## Summary
- Pete Salzmann retired as Immunovant CEO and Director; Eric Venker (Roivant President & COO) appointed CEO; Tiago Girao named CFO.
- IND cleared for IMVT-1402 in Sjögren’s Disease; registrational study expected summer 2025.
- Proof-of-concept study initiated for IMVT-1402 in Cutaneous Lupus Erythematosus (CLE).
- Roivant to lead Immunovant investor relations; cash runway supports through Graves' Disease readout in 2027.
- Robert Susman and Jacob Bauer join Immunovant Board; George Migausky steps down.

## SEC filing metadata
- accession: 0001140361-25-014642
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2025-04-21T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036125014642/0001140361-25-014642-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036125014642/ef20047653_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-014642
- JSON: https://secwatch.observer/filing/0001140361-25-014642.json
- Plain text: https://secwatch.observer/filing/0001140361-25-014642.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.